Singapore markets closed

Oragenics, Inc. (0A64.L)

LSE - LSE Delayed Price. Currency in USD
Add to watchlist
1.4593+0.0393 (+2.77%)
At close: 01:32PM GMT
Full screen
Previous close1.4200
Open1.4593
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range1.4593 - 1.4593
52-week range1.3600 - 7.4500
Volume38
Avg. volume357
Market capN/A
Beta (5Y monthly)0.29
PE ratio (TTM)N/A
EPS (TTM)-0.1420
Earnings date12 Apr 2024 - 16 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

    SARASOTA, Fla., March 18, 2024--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. James "Jim" Kelly, Neurologist, as its Chief Medical Officer, to oversee its upcoming Phase II clinical trial. Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion. ONP-002 i

  • Insider Monkey

    15 Highest Quality Probiotics For Gut Health

    In this article, we will be taking a look at the 15 highest quality probiotics for gut health. If you do not want to learn about the global probiotic market, head straight to the 5 Highest Quality Probiotics For Gut Health. Achieving optimal gut health is paramount for overall well-being, and selecting the highest quality […]

  • Business Wire

    Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

    SARASOTA, Fla., March 05, 2024--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it is preparing to undertake the final steps of GMP manufacturing and formulation of its drug candidate for its expected Phase IIA clinical trial. The drug candidate is expected to be combined with its novel intranasal device, for the treatment of mild Traumatic Brain Injury, aka concussion. Oragenic